Stealth BioTherapeutics Corp MITO
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 23.54M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -6.40
- Beta
- 1.46
- Short ratio
- 1.77
- Inst. own
- 7.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 17, 2022
- 50-d avg
- 0.315554
- 200-d avg
- 0.368184
- 1y target
- 1.77
Discussion (6)
Sign in to join the discussion
garbage?
This thing is crap
Top Stonks, shut up. Dude.
Let’s gooooo. 7 k shares ????
Hold and be patient for the good news
Primary mitochondrial myopathy as a group affects 1 in 5000. It’s clear Elamipretide is increases exercises tolerance and perhaps can enhance performance in healthy individuals. Despite not meeting the end point of recent phase 3 (which basically only measured one performance metric of walking and was way underpowered when considering all covariates) there was clearly a signal of better physical performance. It’s demonstrated to be safe and no serious AEs whether as IV and SQ. And for Barth Syndrome, it’s essentially FDA approved pending an unexpected catastrophe. Awaiting official announcement and SP will take off. I think Mito has just started to tap into the potential of this preFDA approved drug. And they are working with highly respected clinicians from MGH, UCSD etc.. expect already a BO target from BP.